Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics, Inc. (Nasdaq: BNGO) recently announced the issuance of two new US patents, No. 11,291,999 and No. 11,292,713, by the United States Patent and Trademark Office on April 5, 2022. The ‘999 patent focuses on a novel apparatus for minimizing biopolymer aggregation in nanochannels, enhancing DNA loading cycles. The ‘713 patent expands patent protection for optical genome mapping technology, detailing methods for detecting genomic variants. These patents bolster Bionano's intellectual property portfolio, supporting its goal of advancing genomic insights in clinical research.
Bionano Genomics, Inc. (BNGO), has launched a new integrated genomic scar analysis feature for homologous recombination deficiency (HRD) in its N×Clinical 6.2 software release. This capability allows for a comprehensive, automated analysis of tumor biomarkers from next-generation sequencing and microarray data. It aims to improve therapeutic response stratification across various tumor types. The software can measure genomic instability through three genomic scars, enhancing HRD assessment and supporting clinical trials. Bionano is also collaborating with Friends of Cancer Research on HRD biomarker research.
Bionano Genomics (BNGO) announced a new study showcasing the effectiveness of its optical genome mapping (OGM) technology in characterizing genomic variations in B-cell acute lymphoblastic leukemia (B-ALL). Conducted by University Hospitals Leuven, the study involved 12 subjects and utilized various methods, including OGM and single-cell analysis, to identify genetic variations associated with B-ALL. CEO Erik Holmlin emphasized the growing applications of OGM in cancer research and its potential to complement traditional cytogenetic methods. This advancement underscores OGM's viability as a tool in targeted therapy selection.
Bionano Genomics (BNGO) announces participation in the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022, in New Orleans. The company will showcase its optical genome mapping (OGM) solutions, NxClinical software, and laboratory services. Notable presentations include research on genomic structural variations and homologous recombination deficiency (HRD) analysis. Bionano will also introduce NxClinical version 6.2, enhancing HRD analysis capabilities. This participation aims to demonstrate the potential impact of their solutions in cancer research.
Bionano Genomics (BNGO) announced the 2022 China Symposium, scheduled for March 26, featuring 9 presentations from leading Chinese researchers on optical genome mapping (OGM) applications. Topics include human fertility, prenatal genetics, hematological disorders, and solid tumors. Key speakers include Bionano’s CEO Erik Holmlin and CMO Alka Chaubey, who will discuss highlights from the 2022 global symposium. This event underscores Bionano's global commitment to genomic discovery and expanding its community in China.
Bionano Genomics, known for its innovations in optical genome mapping, has announced that CEO Erik Holmlin will present at the 2022 Maxim Virtual Growth Conference. This event will take place on March 30, 2022, at 12:30 PM PT/3:30 PM ET. The conference can be accessed via the M-Vest platform, where participants can register and view the presentation. Bionano aims to transform genome analysis through its Saphyr® system and NxClinical™ software, addressing critical questions in biology and medicine.
Bionano Genomics is participating in the ACMG Annual Clinical Genetics Meeting from March 23–26, 2022, showcasing its complete product portfolio for the first time. Attendees will include combined teams exhibiting Optical Genome Mapping Solutions, Testing Services, and Software. Six scientific posters will discuss advancements in clinical genetics research, particularly for rare undiagnosed genetic diseases. Bionano aims to support genetic clinicians and researchers with enhanced solutions, promoting discovery and improving diagnostics for patients with genetic disorders.
Bionano Genomics (BNGO) announced the validation of its optical genome mapping (OGM) technology in detecting structural variants (SVs) in hematological neoplasms. The study, involving 59 samples, showed OGM's 98.7% sensitivity and 100% specificity, outperforming traditional methods like karyotyping and FISH. OGM also detected additional chromosomal aberrations in cases where traditional methods failed. Researchers suggested OGM as a potential first-tier test in clinical settings, enhancing the identification of new therapeutic targets. The study reflects increasing evidence for OGM's efficacy in routine use.
Bionano Genomics (BNGO) announced that its management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. CEO Erik Holmlin is scheduled to deliver a corporate overview on March 15, 2022, at 5:40 am PT/8:40 am ET. The presentation will be accessible on Bionano’s Investors section on their website. The company specializes in optical genome mapping and offers software solutions for genomic data visualization and interpretation, aiming to revolutionize genome analysis in research and diagnostics.
Bionano Genomics (BNGO) announced the appointment of Dr. Aleks Rajkovic to its board of directors. Dr. Rajkovic, currently the Chief Genomics Officer at UCSF, brings extensive expertise in genomic medicine, including reproductive health and genetic screening. His appointment aims to enhance Bionano's efforts in expanding the capabilities of optical genome mapping (OGM) and its applications in clinical research and patient management. The company continues to focus on revolutionizing genomic analysis with its Saphyr® system and related software solutions.